Drug Type Small molecule drug |
Synonyms ASN 007A, ASN-0007, ERAS 007 + [1] |
Target |
Mechanism ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization Asana BioSciences LLCStartup |
Active Organization |
Inactive Organization Asana BioSciences LLCStartup |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | US | 20 Sep 2021 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | US | 20 Sep 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 07 May 2021 | |
Metastatic Solid Tumor | Phase 2 | US | 07 May 2021 | |
Gastrointestinal Neoplasms | Phase 2 | US | - | |
BRAF V600E mutant Colorectal Cancer | Phase 1 | US | 20 Sep 2021 | |
colon cancer liver metastasis | Phase 1 | US | Asana BioSciences LLCStartup | 19 Jan 2018 |
Metastatic colon cancer | Phase 1 | US | Asana BioSciences LLCStartup | 19 Jan 2018 |
Metastatic melanoma | Phase 1 | US | Asana BioSciences LLCStartup | 19 Jan 2018 |
metastatic non-small cell lung cancer | Phase 1 | US | Asana BioSciences LLCStartup | 19 Jan 2018 |
Phase 1/2 | BRAF V600E mutant Colorectal Cancer BRAF V600E mutation | 19 | ueajhdanba(ytyruidjui) = 26.3% kvexepmnxy (ezqheamacg ) View more | Positive | 24 May 2024 | ||
Phase 1/2 | BRAF V600E mutant Colorectal Cancer BRAF V600E | 12 | lnwkobabtd(wdsgycpkwd) = yxzljzvlwu opetbuqjfj (eteurvtpbl ) View more | Positive | 31 May 2023 | ||
Phase 1/2 | RAS mutant Colorectal Cancer | KRAS mutant pancreatic ductal adenocarcinoma KRAS Mutantion | NRAS Mutantion | 30 | fsneksamwq(gfcyjvgfiy) = kwnszdnhpg tykebwnxir (altrwvavex ) View more | Positive | 26 May 2023 | ||
Phase 1/2 | - | nqxidvdtht(ypbrjwhocw) = Monitorable and manageable adverse event (AE) profile with mostly grade 1 and 2 treatment-related AEs obpqsaspmo (tifwlsfsrq ) View more | Positive | 12 Oct 2022 | |||
NCT03415126 (AACR2019) Manual | Phase 1 | RAS/RAF mutation Solid Tumors RAS Mutation | RAF Mutation | MEK Mutation | - | cieogqqpca(ymwutiqkbv) = 40mg QD and 250mg QW,respectively ergsblomix (oqbkwmjpas ) View more | Positive | 01 Dec 2019 |